LncRNA ADPGK-AS1 promotes pancreatic cancer progression through activating ZEB1-mediated epithelial–mesenchymal transition

References

• Li Y, Vandenboom TG, 2nd, Wang Z, Kong D, Ali S, Philip PA, Sarkar FH. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 2010;70(4):1486–95. doi:10.1158/0008-5472.CAN-09-2792. PMID:20124483.
   PubMed Web of Science ®Google Scholar
• Ali S, Dubaybo H, Brand RE, Sarkar FH. Differential expression of MicroRNAs in tissues and plasma Co-exists as a biomarker for pancreatic cancer. J Cancer Sci Ther. 2015;7(11):336–46. doi:10.4172/1948-5956.1000372. PMID:26819679.
   PubMedGoogle Scholar
• Chakraborty S, Baine MJ, Sasson AR, Batra SK. Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta. 2011;1815(1):44–64. doi:10.1016/j.bbcan.2010.09.002. PMID:20888394.
   PubMed Web of Science ®Google Scholar
• Peng T, Zhou W, Guo F, Wu HS, Wang CY, Wang L, Yang ZY. Centrosomal protein 55 activates NF-kappaB signalling and promotes pancreatic cancer cells aggressiveness. Sci Rep. 2017;7(1):5925. doi:10.1038/s41598-017-06132-z. PMID:28724890.
   PubMedGoogle Scholar
• Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013;144(6):1316–26. doi:10.1053/j.gastro.2013.01.078. PMID:23622141.
   PubMed Web of Science ®Google Scholar
• Harazono Y, Muramatsu T, Endo H, Uzawa N, Kawano T, Harada K, Inazawa J, Kozaki K. miR-655 Is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2. PLoS One. 2013;8(5):e62757. doi:10.1371/journal.pone.0062757. PMID:23690952.
   PubMed Web of Science ®Google Scholar
• Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E, Hahn SA. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;26(30):4442–52. doi:10.1038/sj.onc.1210228. PMID:17237814.
   PubMed Web of Science ®Google Scholar
• Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10(5):593–601. doi:10.1038/ncb1722. PMID:18376396.
   PubMed Web of Science ®Google Scholar
• Torres A, Kozak J, Korolczuk A, Rycak D, Wdowiak P, Maciejewski R, Torres K. Locked nucleic acid-inhibitor of miR-205 decreases endometrial cancer cells proliferation in vitro and in vivo. Oncotarget. 2016;7(45):73651–63. doi:10.18632/oncotarget.12043. PMID:27655663.
   PubMedGoogle Scholar
• Zhong G, Xiong X. miR-205 promotes proliferation and invasion of laryngeal squamous cell carcinoma by suppressing CDK2AP1 expression. Biol Res. 2015;48:60. doi:10.1186/s40659-015-0052-5. PMID:26515287.
   PubMed Web of Science ®Google Scholar
• Niu K, Shen W, Zhang Y, Zhao Y, Lu Y. MiR-205 promotes motility of ovarian cancer cells via targeting ZEB1. Gene. 2015;574(2):330–6. doi:10.1016/j.gene.2015.08.017. PMID:26275944.
   PubMed Web of Science ®Google Scholar
• Bai J, Zhu X, Ma J, Wang W. miR-205 regulates A549 cells proliferation by targeting PTEN. Int J Clin Exp Pathol. 2015;8(2):1175–83. PMID:25973003.
   PubMed Web of Science ®Google Scholar
• Mittal A, Chitkara D, Behrman SW, Mahato RI. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Biomaterials. 2014;35(25):7077–87. doi:10.1016/j.biomaterials.2014.04.053. PMID:24836307.
   PubMed Web of Science ®Google Scholar
• Pan Y, Li C, Chen J, Zhang K, Chu X, Wang R, Chen L. The emerging roles of long noncoding RNA ROR (lincRNA-ROR) and its possible mechanisms in human cancers. Cell Physiol Biochem. 2016;40(1–2):219–29. doi:10.1159/000452539. PMID:27855392.
   PubMed Web of Science ®Google Scholar
• Zhang A, Xu M, Mo YY. Role of the lncRNA-p53 regulatory network in cancer. J Mol Cell Biol. 2014;6(3):181–91. doi:10.1093/jmcb/mju013. PMID:24721780.
   PubMed Web of Science ®Google Scholar
• Martens-Uzunova ES, Bottcher R, Croce CM, Jenster G, Visakorpi T, Calin GA. Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 2014;65(6):1140–51. doi:10.1016/j.eururo.2013.12.003. PMID:24373479.
   PubMed Web of Science ®Google Scholar
• Li X, Wu Z, Fu X, Han W. lncRNAs: insights into their function and mechanics in underlying disorders. Mutat Res Rev Mutat Res. 2014;762:1–21. doi:10.1016/j.mrrev.2014.04.002. PMID:25485593.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu Y, Feng L, Li F, Sun Z, Wu T, Shi X, Li J, Li X. Comprehensive characterization of lncRNA-mRNA related ceRNA network across 12 major cancers. Oncotarget. 2016;7(39):64148–67. doi:10.18632/oncotarget.11637. PMID:27580177.
   PubMed Web of Science ®Google Scholar
• Liang WC, Fu WM, Wong CW, Wang Y, Wang WM, Hu GX, Zhang L, Xiao LJ, Wan DC, Zhang JF, et al. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. Oncotarget. 2015;6(26):22513–25. doi:10.18632/oncotarget.4154. PMID:26068968.
   PubMedGoogle Scholar
• Song X, Cao G, Jing L, Lin S, Wang X, Zhang J, Wang M, Liu W, Lv C. Analysing the relationship between lncRNA and protein-coding gene and the role of lncRNA as ceRNA in pulmonary fibrosis. J Cell Mol Med. 2014;18(6):991–1003. doi:10.1111/jcmm.12243. PMID:24702795.
   PubMed Web of Science ®Google Scholar
• Jalali S, Bhartiya D, Lalwani MK, Sivasubbu S, Scaria V. Systematic transcriptome wide analysis of lncRNA-miRNA interactions. PLoS One. 2013;8(2):e53823. doi:10.1371/journal.pone.0053823. PMID:23405074.
   PubMed Web of Science ®Google Scholar
• Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007;98(10):1512–20. doi:10.1111/j.1349-7006.2007.00550.x. PMID:17645776.
   PubMed Web of Science ®Google Scholar
• Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420–8. doi:10.1172/JCI39104. PMID:19487818.
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhou BP. Snail: More than EMT. Cell Adh Migr. 2010;4(2):199–203. PMID:20168078.
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90. doi:10.1016/j.cell.2009.11.007. PMID:19945376.
   PubMed Web of Science ®Google Scholar
• Meidhof S, Brabletz S, Lehmann W, Preca BT, Mock K, Ruh M, Schuler J, Berthold M, Weber A, Burk U, et al. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol Med. 2015;7(6):831–47. doi:10.15252/emmm.201404396. PMID:25872941.
   PubMed Web of Science ®Google Scholar
• Krebs AM, Mitschke J, Lasierra Losada M, Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D, Reichardt W, Bronsert P, et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol. 2017;19(5):518–29. doi:10.1038/ncb3513. PMID:28414315.
   PubMed Web of Science ®Google Scholar
• Mondal G, Almawash S, Chaudhary AK, Mahato RI. EGFR-targeted cationic polymeric mixed micelles for codelivery of Gemcitabine and miR-205 for treating advanced pancreatic cancer. Mol Pharm. 2017;14(9):3121–33. doi:10.1021/acs.molpharmaceut.7b00355. PMID:28719220.
   PubMed Web of Science ®Google Scholar
• Paik WH, Song BJ, Kim HW, Kim HR, Hwang JH. MicroRNA-200c as a prognostic biomarker for pancreatic cancer. Korean J Gastroenterol. 2015;66(4):215–20. doi:10.4166/kjg.2015.66.4.215. PMID:26493507.
   PubMedGoogle Scholar
• He B, Bai Y, Kang W, Zhang X, Jiang X. LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p. Am J Cancer Res. 2017;7(8):1704–13. PMID:28861326.
   PubMed Web of Science ®Google Scholar
• Yang W, Hong L, Xu X, Wang Q, Huang J, Jiang L. LncRNA GAS5 suppresses the tumorigenesis of cervical cancer by downregulating miR-196a and miR-205. Tumour Biol. 2017;39(7):1010428317711315. doi:10.1177/1010428317711315. PMID:28671039.
   PubMedGoogle Scholar
• Hirata H, Hinoda Y, Shahryari V, Deng G, Nakajima K, Tabatabai ZL, Ishii N, Dahiya R. Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and interacts with miR-205. Cancer Res. 2015;75(7):1322–31. doi:10.1158/0008-5472.CAN-14-2931. PMID:25600645.
   PubMed Web of Science ®Google Scholar
• Guo Q, Qin W. DKK3 blocked translocation of beta-catenin/EMT induced by hypoxia and improved gemcitabine therapeutic effect in pancreatic cancer Bxpc-3 cell. J Cell Mol Med. 2015;19(12):2832–41. doi:10.1111/jcmm.12675. PMID:26395974.
   PubMed Web of Science ®Google Scholar
• Cao LY, Yang J, Fu XG, Lin YH, Lin F, Huang BY. [The MicroRNA miR-205 inhibits epithelial-messenchymal transition in HK-2 cells by down-regulating ZEB1 and ZEB2 expressions]. Nan Fang Yi Ke Da Xue Xue Bao. 2016;36(12):1700–05. PMID:27998868.
   PubMedGoogle Scholar
• Lee JY, Park MK, Park JH, Lee HJ, Shin DH, Kang Y, Lee CH, Kong G. Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer. Oncogene. 2014;33(10):1325–35. doi:10.1038/onc.2013.53. PMID:23474752.
   PubMed Web of Science ®Google Scholar
• Zhao L, Sun H, Kong H, Chen Z, Chen B, Zhou M. The Lncrna-TUG1/EZH2 axis promotes pancreatic cancer cell proliferation, migration and EMT phenotype formation through sponging Mir-382. Cell Physiol Biochem. 2017;42(6):2145–58. doi:10.1159/000479990. PMID:28813705.
   PubMed Web of Science ®Google Scholar
• Benlhabib H, Guo W, Pierce BM, Mendelson CR. The miR-200 family and its targets regulate type II cell differentiation in human fetal lung. J Biol Chem. 2015;290(37):22409–22. doi:10.1074/jbc.M114.636068. PMID:26203191.
   PubMed Web of Science ®Google Scholar